Atea Pharmaceuticals Inc. (AVIR) Social Stream
ATEA PHARMACEUTICALS INC (AVIR) Price Targets From Analysts
Use the tables below to see what analysts covering ATEA PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 5 | $20 | $14 | $16.666 | $3.18 | 424.09% |
| 2021-11-18 | 5 | $16 | $11 | $13.666 | $3.18 | 329.75% |
| 2021-12-15 | 4 | $16 | $11 | $13.666 | $3.18 | 329.75% |
| 2022-01-04 | 4 | $14 | $10 | $11.666 | $3.18 | 266.86% |
| 2022-01-06 | 4 | $11 | $7 | $9.333 | $3.18 | 193.49% |
| 2022-01-31 | 4 | $11 | $6 | $9 | $3.18 | 183.02% |
| 2022-02-15 | 4 | $10 | $6 | $8.666 | $3.18 | 172.52% |
| 2022-02-28 | 4 | $10 | $6 | $8.333 | $3.18 | 162.04% |
| 2022-05-10 | 4 | $9 | $6 | $7.666 | $3.18 | 141.07% |
| 2022-08-09 | 4 | $11 | $6 | $8.666 | $3.18 | 172.52% |
| 2022-08-15 | 4 | $12 | $7 | $9.333 | $3.18 | 193.49% |
| 2022-10-12 | 4 | $12 | $7 | $9 | $3.18 | 183.02% |
| 2022-11-08 | 4 | $12 | $7 | $9 | $3.18 | 183.02% |
| 2023-01-24 | 4 | $12 | $4 | $8 | $3.18 | 151.57% |
| 2023-03-01 | 4 | $12 | $4 | $7.333 | $3.18 | 130.6% |
| 2023-08-08 | 4 | $8 | $4 | $5.333 | $3.18 | 67.7% |
| 2023-08-17 | 4 | $4 | $4 | $4 | $3.18 | 25.79% |
The Trend in the Analyst Price Target
Over the past 15 months, AVIR's average price target has gone down $3.67.
Over the past 44 weeks, AVIR's average upside potential has been 63.84%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-10-12 | 4 | 12 | 7 | 9.000 | 5.30 | 69.81% |
| 2023-03-01 | 4 | 12 | 4 | 6.666 | 3.25 | 105.11% |
| 2023-03-01 | 4 | 12 | 4 | 7.333 | 3.25 | 125.63% |
| 2023-03-16 | 4 | 8 | 4 | 5.333 | 3.68 | 44.92% |
| 2023-05-08 | 4 | 8 | 4 | 5.333 | 3.40 | 56.85% |
AVIR Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3.17 | 1 | 0 | 1 | 1 | 1 | 4 |
The Trend in the Broker Recommendations
Over the past 52 weeks, AVIR's average broker recommendation rating worsened by 0.25.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ATEA PHARMACEUTICALS INC's average analyst price target is higher than 180.73% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, ATEA PHARMACEUTICALS INC's number of analysts covering the stock is greater than 280.25% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, ATEA PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is higher than 1505.46% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ATEA PHARMACEUTICALS INC's variance in analysts' estimates is lower than -582.51% of them.
In the Pharmaceutical Products industry, LMDX, EQRX, and VALN are the three stocks most similar to ATEA PHARMACEUTICALS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for AVIR? Use POWR Ratings for clearer insight into price direction.